🚨 Exiting start to 2026 for the @SIFT_RCT 🚀 50 patients included in Norway 🇳🇴 and hopefully expansion to other Skandinavian countries 🇩🇰🇸🇪🤩 Thanks to all PIs and great colleagues for our collaboration ❤️🙏
In the latest #ESOBlog post, "Tenecteplase in the Extended Time Window," @vojtech_no explores the key question: "Where do we currently stand & how should evidence guide practice?" incorporating insights from the latest trials into his analysis 🔗eso-stroke.org/tenecteplase-…#stroke
The Focused Workshop in Ohrid was an enriching experience! Residents&neurologists learned about patients w rare causes of stroke from CADASIL to CARASIL, Fabry disease to Fibromuscular dysplasia& Angels symposium to MELAS
#stroke#neurology#stroketwitter@UKIMedu@arsovska_anita
Large, pooled analysis finds a poorer safety profile for Tenecteplase 0.4 mg/kg than standard-dose alteplase in acute ischemic stroke treated within 4.5 hours. A lower 0.25 mg/kg dose should be considered instead. #AHAJournals@vojtech_no@Bergen_Strokeahajrnls.org/45N13Im
Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR‐TEST and NOR‐TEST 2A | Journal of the American Heart Association ahajournals.org/doi/full/10.…
#nsc2023@nsc2023@NordicStroke#Kuopio
Ulrike Waje-Andreassen - "Contribution of ultrasound examinations in the etiologic evaluation of patients with ischemic stroke/TIA"